期刊文献+

结直肠癌患者胸苷酸磷酸化酶活性与XELOX新辅助化疗疗效的关系 被引量:1

The correlation between enzymatic activity of thymidine phosphorylase and the efficacy of XELOX NC in colorectal cancer patients
下载PDF
导出
摘要 目的研究结直肠癌中胸苷酸磷酸化酶(TP)活性与XELOX新辅助化疗疗效之间的关系。方法收集64例采用XELOX方案化疗的结直肠癌患者临床资料,根据TP酶活性不同分为TP高酶活性组(32例)和TP低酶活性组(32例),统计两组患者的化疗效果以及术后5年生存期。结果 TP高酶活性组患者化疗后病灶减小程度高于TP低酶活性组,周围组织的浸润程度低于TP低酶活性组,同时患者的术后生存率亦高于TP低酶活性组,差异均具有统计学意义(P﹤0.05)。结论结直肠癌中胸苷酸磷酸化酶活性越高,XELOX化疗敏感性越高,化疗效果越好,预后相对优于TP酶活性低者。 Objective To study the correlation between thymidine phosphorylase (TP) and XELOX neoadjuvant chemotherapy. Method 64 cases of colorectal cancer patients who were administered with XELOX regimen were enrolled in this study, and were then stratified as either high TP group(n=32) or low TP group(n=32) by individual TP enzymatic activity, the efficacy and 5-year survival of both groups were analyzed. Result The TP lesions shrank more in the high TP group compared with that of the low TP group, besides, a less infiltration and a higher postoperative survival rate were observed in the low TP group, and all differences were of statistical significance (P〈0.05). Conclusion TP enzymatic activity is higher, the XELOX is more sensitive, the effect of chemotherapy is better in colorectal cancer.
出处 《癌症进展》 2016年第3期286-288,共3页 Oncology Progress
关键词 结直肠癌 胸苷酸磷酸化酶 酶活性 新辅助化疗 colorectal cancer TP enzyme activity NC
  • 相关文献

参考文献3

二级参考文献15

  • 1Carolin Tonus,Gero Neupert,Markus Sellinger.Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK[J].World Journal of Gastroenterology,2006,12(43):7007-7011. 被引量:14
  • 2Sae‐Won Han,Hyun‐Jung Lee,Jeong Mo Bae,Nam‐Yun Cho,Kyung‐Hun Lee,Tae‐Yong Kim,Do‐Youn Oh,Seock‐Ah Im,Yung‐Jue Bang,Seung‐Yong Jeong,Kyu Joo Park,Jae‐Gahb Park,Gyeong Hoon Kang,Tae‐You Kim.Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer[J].Int J Cancer.2012(9)
  • 3Ming‐Yii Huang,Hsiang‐Lin Tsai,Chih‐Hung Lin,Ching‐Wen Huang,Cheng‐Jen Ma,Chun‐Ming Huang,Chee‐Yin Chai,Jaw‐Yuan Wang.Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX‐4 adjuvant chemotherapy[J].J Surg Oncol.2013(7)
  • 4Elena De Mattia,Giuseppe Toffoli,Jerry Polesel,Mario D’Andrea,Giuseppe Corona,Vittorina Zagonel,Angela Buonadonna,Eva Dreussi,Erika Cecchin.Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment[J].Pharmacogenetics and Genomics.2013(10)
  • 5Zhi Peng,Qianqian Wang,Jing Gao,Zhaoning Ji,Jiajia Yuan,Ye Tian,Lin Shen.Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis[J].Cancer Chemotherapy and Pharmacology.2013(2)
  • 6Kensuke Kumamoto,Keiichiro Ishibashi,Norimichi Okada,Yusuke Tajima,Kouki Kuwabara,Yoichi Kumagai,Hiroyuki Baba,Norihiro Haga,Hideyuki Ishida.Polymorphisms of GSTP1, ERCC2 and TS?3’UTR are associated with the clinicaloutcome of mFOLFOX6 in colorectal cancer patients[J].Oncology Letters.2013(3)
  • 7Kyung-Hun Lee,Hye Jung Chang,Sae-Won Han,Do-Youn Oh,Seock-Ah Im,Yung-Jue Bang,Sun Young Kim,Keun-Wook Lee,Jee Hyun Kim,Yong Sang Hong,Tae Won Kim,Young Suk Park,Won Ki Kang,Sang Joon Shin,Joong Bae Ahn,Gyeong Hoon Kang,Seung-Yong Jeong,Kyu Joo Park,Jae-Gahb Park,Tae-You Kim.Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer[J].Cancer Chemotherapy and Pharmacology.2013(4)
  • 8Tetsuya Minegaki,Kohji Takara,Ryohei Hamaguchi,Masayuki Tsujimoto,Kohshi Nishiguchi.Factors affecting the sensitivity of human-derived esophageal carcinomacell lines to 5-fluorouracil and cisplatin[J].Oncology Letters.2013(2)
  • 9Mafalda M Dias,Ross A McKinnon,Michael J Sorich.Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis[J].Pharmacogenomics.2012(8)
  • 10Sotaro Sadahiro,Toshiyuki Suzuki,Akira Tanaka,Kazutake Okada,Hideki Nagase,Junji Uchida.Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer[J].Cancer Chemotherapy and Pharmacology.2012(2)

共引文献13

同被引文献6

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部